

## Amniotics publishes merger document regarding the merger with Magle Group

Today, Amniotics AB (publ) (“Amniotics”) announces that the merger document regarding the merger (the “Merger”) with Magle Chemoswed Holding AB has been published on the companies’ websites: [www.amniotics.com](http://www.amniotics.com) and [www.maglegroup.com](http://www.maglegroup.com). As previously announced, the Merger is expected to be completed on or about 3 October 2024.

**For more information please contact:**

Marcus Larsson, CEO

Email: [ml@amniotics.com](mailto:ml@amniotics.com)

Telephone: +46 (0) 763 08 40 91

For administrative questions regarding the offer, please contact your bank or the nominee registered as holder of your shares.

**About Amniotics**

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking. Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies. Amniotics is headquartered in Lund, Sweden. The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB.

**Important Information**

*In the information below, “this press release” refers to this document, its content or part thereof, oral presentations, question papers and written or oral material discussed or distributed in connection therewith. This press release is not a notice to attend an extraordinary general meeting or a merger document. This press release is also not an offer to sell, or a solicitation or invitation to submit an offer to buy, acquire or subscribe for, securities, or an incentive to make any investment, and there will be no sale of securities in jurisdictions where such an offer, request or sale would be prohibited without registration or qualification under such jurisdiction’s securities law. Decisions regarding the Merger shall be made solely on the basis of information stated in the merger document relating to the Merger, and to independent analyses of the information therein. You should read the merger document, that is available on Amniotics’ and Magle Group’s websites: [www.amniotics.com](http://www.amniotics.com) and [www.maglegroup.com](http://www.maglegroup.com), to obtain more complete information on the Merger. You should also do an independent analysis of the information contained therein and the merger document before making an investment decision.*

*This press release contains forward-looking information. Forward-looking information is inherently associated with known and unknown risks, uncertainties, assumptions and other factors, as it relates to circumstances and depends on circumstances that occur in the future, whether within or outside the respective companies or the, through the Merger created “**New Magle Group’s**” control. Such factors may cause actual results, performance and actual development to deviate significantly from what is expressed or implied in the forward-looking information. Although each company’s management believes that their expectations stated in the forward-looking information are reasonable based on such information that is available to them, no guarantee is given that such forward-looking information will prove to be accurate. Undue weight should not be given to forward-looking information. The forward-looking information applies only to the day of this press release and neither Magle Group nor Amniotics undertake any obligation to update the forward-looking information beyond what is required pursuant to applicable law. Magle Group’ and Amniotics’ past performance does not guarantee, and does not represent, the future performance of New Magle Group. Furthermore, Magle Group, Amniotics and their respective subsidiaries, senior executives, employees and agents undertake no obligation to review, update or confirm expectations or estimates, or revise forward-looking information to reflect events that occur, or circumstances that arise, in relation to the content of the press release. Furthermore, it is not certain that the Merger will be carried out in the manner and within the time frame described in this press release or at all.*

## **Attachments**

---

[Amniotics publishes merger document regarding the merger with Magle Group](#)